As for non-small cell lung cancer, acriflavine, which inhibits the development of HIF-1α/β dimers [63], panobinostat, which degrades HIF-1α and histone deacetylase 4 (HDAC4) [62], and oroxylin A, which binds directly to the HIF-1α bHLH-PAS domain [64], can reduce hypoxia-induced cisplatin resistance. The gene discussed is HIF1A; the disease is non-small cell lung carcinoma.